Project Open - Use of Administrative Health Data to Increase Diabetic Retinopathy Screening
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05074342|
Recruitment Status : Not yet recruiting
First Posted : October 12, 2021
Last Update Posted : October 25, 2021
Early detection through regular diabetic retinopathy screening (DRS) is an effective method of preventing vision loss by enabling earlier intervention and timely treatment. It is recommended that all people with diabetes receive regular DRS, either annually or bi-annually. Current DRS practice in Canada, however, falls remarkably short of recommended DRS rates resulting in preventable vision loss.
In this project the investigators use population health-based approach to diabetes care. Linked provincial administrative data will be leveraged to consistently identify all those that have not had DRS in 425 days with the goal to improve outcomes, equity and potentially reduce the cost of care delivery.
|Condition or disease|
|Diabetes Diabetic Retinopathy|
|Study Type :||Observational|
|Estimated Enrollment :||2000 participants|
|Official Title:||Guiding Primary Care Diabetic Retinopathy Screening in Canada Through the Use of Provincial Healthcare Administrative Data|
|Estimated Study Start Date :||October 15, 2021|
|Estimated Primary Completion Date :||December 31, 2022|
|Estimated Study Completion Date :||December 31, 2023|
- The provision of a DRS status list to primary health care settings will increase the rate of annual DR screening in patients with type 1 or type 2 diabetes who have attended the centres. [ Time Frame: 425 days ]To increase the screening rate of individuals who are at risk for DR within the primary care settings, and to refer to treatment those at risk of vision loss.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05074342
|Contact: Olivera Sutakovic, MD||416-603-5800 ext 5125||Olivera.Sutakovic@uhn.ca|
|Contact: Jim Bowen, BScPhm, MSc, RPhfirstname.lastname@example.org|
|University Health Network|
|Toronto, Ontarioa, Canada, M5T 2S8|